Report ID: PMRREP34639
Number of Pages: 176
Format: PPT*, PDF, EXCEL
Industry: Healthcare
Published Date: July-2024
1. Executive Summary
1.1. Global Lipid Nanoparticle Manufacturing Market Snapshot, 2024 and 2031
1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Product Adoption Analysis
3.2. Technology Assessment
3.3. Regulatory Landscape
3.4. Supply Chain Analysis
3.5. Key Deals and Mergers
3.6. PESTLE Analysis
3.7. Porter's Five Force Analysis
4. Global Lipid Nanoparticle Manufacturing Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
4.1. Key Highlights
4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Mn) Analysis, 2018-2022
4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2023-2031
4.3. Global Lipid Nanoparticle Manufacturing Market Outlook: Type of LNP
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Mn) Analysis, By Type of LNP, 2018 - 2022
4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2023 - 2031
4.3.3.1. Solid Lipid Nanoparticles (SLNs)
4.3.3.2. Nanostructured Lipid Carriers (NLCs)
4.4. Market Attractiveness Analysis: Type of LNP
4.5. Global Lipid Nanoparticle Manufacturing Market Outlook: Therapeutic Area
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Mn) Analysis, By Therapeutic Area, 2018 - 2022
4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2023 - 2031
4.5.3.1. Infectious Diseases
4.5.3.2. Rare Diseases
4.5.3.3. Oncological Disorders
4.5.3.4. Neurodegenerative Disorders
4.5.3.5. Others
4.6. Market Attractiveness Analysis: Therapeutic Area
4.7. Global Lipid Nanoparticle Manufacturing Market Outlook: End User
4.7.1. Introduction / Key Findings
4.7.2. Historical Market Size (US$ Mn) Analysis, By End User, 2018 - 2022
4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2023 - 2031
4.7.3.1. Pharmaceutical and Biotechnology Companies
4.7.3.2. Academic & Research Institutes
4.7.3.3. Others
4.8. Market Attractiveness Analysis: End User
5. Global Lipid Nanoparticle Manufacturing Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2018 - 2022
5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2023 - 2031
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Lipid Nanoparticle Manufacturing Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
6.2.1. By Country
6.2.2. By Type of LNP
6.2.3. By Therapeutic Area
6.2.4. By End User
6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2023 - 2031
6.4.1. Solid Lipid Nanoparticles (SLNs)
6.4.2. Nanostructured Lipid Carriers (NLCs)
6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2023 - 2031
6.5.1. Infectious Diseases
6.5.2. Rare Diseases
6.5.3. Oncological Disorders
6.5.4. Neurodegenerative Disorders
6.5.5. Others
6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2023 - 2031
6.6.1. Pharmaceutical and Biotechnology Companies
6.6.2. Academic & Research Institutes
6.6.3. Others
6.7. Market Attractiveness Analysis
7. Europe Lipid Nanoparticle Manufacturing Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
7.2.1. By Country
7.2.2. By Type of LNP
7.2.3. By Therapeutic Area
7.2.4. By End User
7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Türkiye
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2023 - 2031
7.4.1. Solid Lipid Nanoparticles (SLNs)
7.4.2. Nanostructured Lipid Carriers (NLCs)
7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2023 - 2031
7.5.1. Infectious Diseases
7.5.2. Rare Diseases
7.5.3. Oncological Disorders
7.5.4. Neurodegenerative Disorders
7.5.5. Others
7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2023 - 2031
7.6.1. Pharmaceutical and Biotechnology Companies
7.6.2. Academic & Research Institutes
7.6.3. Others
7.7. Market Attractiveness Analysis
8. East Asia Lipid Nanoparticle Manufacturing Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
8.2.1. By Country
8.2.2. By Type of LNP
8.2.3. By Therapeutic Area
8.2.4. By End User
8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2023 - 2031
8.4.1. Solid Lipid Nanoparticles (SLNs)
8.4.2. Nanostructured Lipid Carriers (NLCs)
8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2023 - 2031
8.5.1. Infectious Diseases
8.5.2. Rare Diseases
8.5.3. Oncological Disorders
8.5.4. Neurodegenerative Disorders
8.5.5. Others
8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2023 - 2031
8.6.1. Pharmaceutical and Biotechnology Companies
8.6.2. Academic & Research Institutes
8.6.3. Others
8.7. Market Attractiveness Analysis
9. South Asia & Oceania Lipid Nanoparticle Manufacturing Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
9.2.1. By Country
9.2.2. By Type of LNP
9.2.3. By Therapeutic Area
9.2.4. By End User
9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2023 - 2031
9.4.1. Solid Lipid Nanoparticles (SLNs)
9.4.2. Nanostructured Lipid Carriers (NLCs)
9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2023 - 2031
9.5.1. Infectious Diseases
9.5.2. Rare Diseases
9.5.3. Oncological Disorders
9.5.4. Neurodegenerative Disorders
9.5.5. Others
9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2023 - 2031
9.6.1. Pharmaceutical and Biotechnology Companies
9.6.2. Academic & Research Institutes
9.6.3. Others
9.7. Market Attractiveness Analysis
10. Latin America Lipid Nanoparticle Manufacturing Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
10.2.1. By Country
10.2.2. By Type of LNP
10.2.3. By Therapeutic Area
10.2.4. By End User
10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2023 - 2031
10.4.1. Solid Lipid Nanoparticles (SLNs)
10.4.2. Nanostructured Lipid Carriers (NLCs)
10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2023 - 2031
10.5.1. Infectious Diseases
10.5.2. Rare Diseases
10.5.3. Oncological Disorders
10.5.4. Neurodegenerative Disorders
10.5.5. Others
10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2023 - 2031
10.6.1. Pharmaceutical and Biotechnology Companies
10.6.2. Academic & Research Institutes
10.6.3. Others
10.7. Market Attractiveness Analysis
11. Middle East & Africa Lipid Nanoparticle Manufacturing Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
11.2.1. By Country
11.2.2. By Type of LNP
11.2.3. By Therapeutic Area
11.2.4. By End User
11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2023 - 2031
11.4.1. Solid Lipid Nanoparticles (SLNs)
11.4.2. Nanostructured Lipid Carriers (NLCs)
11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2023 - 2031
11.5.1. Infectious Diseases
11.5.2. Rare Diseases
11.5.3. Oncological Disorders
11.5.4. Neurodegenerative Disorders
11.5.5. Others
11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2023 - 2031
11.6.1. Pharmaceutical and Biotechnology Companies
11.6.2. Academic & Research Institutes
11.6.3. Others
11.7. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2023
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Certest Biotec
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Evonik
12.3.2.1. Overview
12.3.2.2. Segments and Products
12.3.2.3. Key Financials
12.3.2.4. Market Developments
12.3.2.5. Market Strategy
12.3.3. Ascendia Pharmaceuticals
12.3.3.1. Overview
12.3.3.2. Segments and Products
12.3.3.3. Key Financials
12.3.3.4. Market Developments
12.3.3.5. Market Strategy
12.3.4. Lonza
12.3.4.1. Overview
12.3.4.2. Segments and Products
12.3.4.3. Key Financials
12.3.4.4. Market Developments
12.3.4.5. Market Strategy
12.3.5. Exelead (Merck KGaA)
12.3.5.1. Overview
12.3.5.2. Segments and Products
12.3.5.3. Key Financials
12.3.5.4. Market Developments
12.3.5.5. Market Strategy
12.3.6. CordenPharma
12.3.6.1. Overview
12.3.6.2. Segments and Products
12.3.6.3. Key Financials
12.3.6.4. Market Developments
12.3.6.5. Market Strategy
12.3.7. Curia Global, Inc.
12.3.7.1. Overview
12.3.7.2. Segments and Products
12.3.7.3. Key Financials
12.3.7.4. Market Developments
12.3.7.5. Market Strategy
12.3.8. Creative Biostructure
12.3.8.1. Overview
12.3.8.2. Segments and Products
12.3.8.3. Key Financials
12.3.8.4. Market Developments
12.3.8.5. Market Strategy
12.3.9. CD Bioparticles
12.3.9.1. Overview
12.3.9.2. Segments and Products
12.3.9.3. Key Financials
12.3.9.4. Market Developments
12.3.9.5. Market Strategy
12.3.10. BOC Sciences
12.3.10.1. Overview
12.3.10.2. Segments and Products
12.3.10.3. Key Financials
12.3.10.4. Market Developments
12.3.10.5. Market Strategy
12.3.11. Acuitas Therapeutics
12.3.11.1. Overview
12.3.11.2. Segments and Products
12.3.11.3. Key Financials
12.3.11.4. Market Developments
12.3.11.5. Market Strategy
12.3.12. ABP Biosciences, LLC
12.3.12.1. Overview
12.3.12.2. Segments and Products
12.3.12.3. Key Financials
12.3.12.4. Market Developments
12.3.12.5. Market Strategy
12.3.13. Recipharm AB
12.3.13.1. Overview
12.3.13.2. Segments and Products
12.3.13.3. Key Financials
12.3.13.4. Market Developments
12.3.13.5. Market Strategy
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
